Diagonal Bio

Executive Summary

Diagonal Bio is a Swedish diagnostics company developing a novel Panviral diagnostic platform designed to deliver high-accuracy, rapid, and cost-effective point-of-care testing. Founded in 2020 and based in Stockholm, the company aims to address critical gaps in infectious disease diagnostics by combining speed and ease-of-use without compromising on quality. Their platform targets multiple viral pathogens simultaneously, offering a versatile tool for healthcare settings where timely diagnosis is crucial. With a focus on reducing dependency on centralized laboratories, Diagonal Bio's technology could significantly improve access to testing in underserved regions and during outbreaks. While still in its early stages as a private company, Diagonal Bio has positioned itself within the rapidly growing point-of-care diagnostics market. The company has not yet disclosed funding rounds or commercial products, suggesting it is likely in the pre-revenue phase. The success of its Panviral platform will depend on achieving regulatory approvals (e.g., CE marking), establishing manufacturing partnerships, and demonstrating clinical utility. Given the competitive landscape and the typical development timelines for diagnostic devices, near-term revenue generation remains uncertain, but the platform's broad pathogen coverage and point-of-care design offer a clear value proposition.

Upcoming Catalysts (preview)

• Q2 2026Completion of Series A funding round to advance platform development60% success
• Q3 2026First strategic partnership with a diagnostics distributor or healthcare provider50% success
• Q1 2027CE marking or regulatory clearance for the Panviral platform in Europe40% success